Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells

References

• Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019 Jan;321(3):288–13. doi:10.1001/jama.2018.19323.
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010 Nov;363(20):1938–1948. doi:10.1056/NEJMra1001389.
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 2018 Feb;378(5):439–448. doi:10.1056/NEJMoa1709866.
   PubMed Web of Science ®Google Scholar
• Lemal R, Tournilhac O. State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019. J Immunother Cancer. 2019;7(1). doi:10.1186/s40425-019-0686-x.
   PubMed Web of Science ®Google Scholar
• Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J, Introna M. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood. 2011;118(12):3301–3310. doi:10.1182/blood-2011-02-336321.
   PubMed Web of Science ®Google Scholar
• Pan K, Guan -X-X, Li Y-Q, Zhao -J-J, Li -J-J, Qiu H-J, Weng D-S, Wang Q-J, Liu Q, Huang L-X, et al. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer. Clin Cancer Res. 2014;20(11):3003–3011. doi:10.1158/1078-0432.CCR-14-0082.
   PubMed Web of Science ®Google Scholar
• Sangiolo D, Martinuzzi E, Todorovic M, Vitaggio K, Vallario A, Jordaney N, Carnevale-Schianca F, Capaldi A, Geuna M, Casorzo L, et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int. Immunol. 2008 Jul;20(7):841–848. doi:10.1093/intimm/dxn042.
   PubMed Web of Science ®Google Scholar
• Schmeel LC, Schmeel FC, Coch C, Schmidt-Wolf IGH. Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2015 May;141(5):839–849. doi:10.1007/s00432-014-1864-3.
   PubMed Web of Science ®Google Scholar
• Zhou Z-Q, Zhao -J-J, Pan Q-Z, Chen C-L, Liu Y, Tang Y, Zhu Q, Weng D-S, Xia J-C. PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer. J Immunother Cancer. 2019 Dec;7(1):228. doi:10.1186/s40425-019-0696-8.
   PubMed Web of Science ®Google Scholar
• Cappuzzello E, Tosi A, Zanovello P, Sommaggio R, Rosato A. Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies. Oncoimmunology. 2016 Aug;5(8):e1199311. doi:10.1080/2162402X.2016.1199311.
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358(11):1160–1174. doi:10.1056/NEJMra0707704.
   PubMed Web of Science ®Google Scholar
• da Silva JL, Cardoso Nunes NC, Izetti P, de Mesquita GG, de Melo AC. Triple negative breast cancer: a thorough review of biomarkers. Crit Rev Oncol Hematol. Elsevier Ireland Ltd. 2020;145:102855. doi:10.1016/j.critrevonc.2019.102855.
   PubMed Web of Science ®Google Scholar
• Keyaerts M, Verschueren J, Bos TJ, Tchouate-Gainkam LO, Peleman C, Breckpot K, Vanhove C, Caveliers V, Bossuyt A, Lahoutte T, et al. Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of d-luciferin: effect on intensity, time kinetics and repeatability of photon emission. Eur J Nucl Med Mol Imaging. 2008 May;35(5):999–1007. doi:10.1007/s00259-007-0664-2.
   PubMed Web of Science ®Google Scholar
• Schoos A, Gabriel C, Knab VM, Fux DA. Activation of HIF-1α by δ-Opioid Receptors Induces COX-2 Expression in Breast Cancer Cells and Leads to Paracrine Activation of Vascular Endothelial Cells. J Pharmacol Exp Ther. 2019;370(3):480-489. doi:10.1124/jpet.119.257501.
   PubMed Web of Science ®Google Scholar
• Tosi A, Dalla Santa S, Cappuzzello E, Marotta C, Walerich D, Del Sal G, Zanovello P, Sommaggio R, Rosato A, . Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1. Oncoimmunology. 2017 Aug;6(8):e1313371. doi:10.1080/2162402X.2017.1313371.
   PubMed Web of Science ®Google Scholar
• Pegoraro S, Ros G, Piazza S, Sommaggio R, Ciani Y, Rosato A, Sgarra R, Del Sal G, Manfioletti G.. HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness.. Oncotarget. 2013 Aug;4(8):1293–1308. doi:10.18632/oncotarget.1136.
   PubMedGoogle Scholar
• Domschke C, Ge Y, Bernhardt I, Schott S, Keim S, Juenger S, Bucur M, Mayer L, Blumenstein M, Rom J, et al. Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial. Cancer Immunol. Immunother. 2013 Jun;62(6):1053–1060. doi:10.1007/s00262-013-1414-x.
   PubMed Web of Science ®Google Scholar
• Gallo S, Sangiolo D, Carnevale Schianca F, Aglietta M, Montemurro F. Treating breast cancer with cell-based approaches: an overview. Expert Opin Biol Ther. 2017;17(10):1255–1264. doi:10.1080/14712598.2017.1356816.
   PubMed Web of Science ®Google Scholar
• Bajgain P, Tawinwung S, D’Elia L, Sukumaran S, Watanabe N, Hoyos V, Lulla P, Brenner MK, Leen AM, Vera JF, et al. CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer. 2018;6(1). doi:10.1186/s40425-018-0347-5.
   PubMedGoogle Scholar
• Introna M, Franceschetti M, Ciocca A, Borleri G, Conti E, Golay J, Rambaldi A. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant. 2006 Nov;38(9):621–627. doi:10.1038/sj.bmt.1705503.
   PubMed Web of Science ®Google Scholar
• Giraudo L, Gammaitoni L, Cangemi M, Rotolo R, Aglietta M, Sangiolo D. Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives. Immunotherapy. 2015 Sep;7(9):999–1010. doi:10.2217/imt.15.61.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao J-X, Pan J-H, Liu Y-S, Xu B-L, Li D, Zhang X-Y, Li J-L, Liu J-L, Wang H-B, et al. Adoptive immunotherapy of cytokine-induced killer cell therapy in the treatment of non-small cell lung cancer. PLoS One. 2014;9(11):e112662. doi:10.1371/journal.pone.0112662.
   PubMed Web of Science ®Google Scholar
• Monteverde M, Milano G, Strola G, Maffi M, Lattanzio L, Vivenza D, Tonissi F, Merlano M, Lo Nigro C. The relevance of ADCC for EGFR targeting: a review of the literature and a clinically-applicable method of assessment in patients.. Crit. Rev. Oncol. Hematol. 2015 Aug;95(2):179–190. doi:10.1016/j.critrevonc.2015.02.014.
   PubMed Web of Science ®Google Scholar
• Del Bano J, Florès-Florès R, Josselin E, Goubard A, Ganier L, Castellano R, Chames P, Baty D, Kerfelec B.. A bispecific antibody-based approach for targeting mesothelin in triple negative breast cancer. Front. Immunol. 2019;10:1593. doi:10.3389/fimmu.2019.01593.
   PubMed Web of Science ®Google Scholar
• Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, et al. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev. 2016;35(4):547–573. doi:10.1007/s10555-016-9653-x.
   PubMed Web of Science ®Google Scholar
• Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, et al. PDX-MI: minimal information for patient-derived tumor xenograft models. Cancer Res. 2017;77(21):e62–e66. doi:10.1158/0008-5472.CAN-17-0582.
   PubMed Web of Science ®Google Scholar
• Anegón I, Cuturi MC, Trinchieri G, Perussia B. Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J Exp Med. 1988 Feb;167(2):452–472. doi:10.1084/jem.167.2.452.
   PubMed Web of Science ®Google Scholar
• Harris DT, Travis WW, Koren HS. Induction of activation antigens on human natural killer cells mediated through the Fc-gamma receptor.. J Immunol. 1989 Oct 1;143(7):2401–2406
   Google Scholar
• Duggan MC, Campbell AR, McMichael EL, Opheim KS, Levine KM, Bhave N, Culbertson MC, Noel T, Yu L, Carson WE, et al. Co-stimulation of the fc receptor and interleukin-12 receptor on human natural killer cells leads to increased expression of cd25. Oncoimmunology. 2018;7(2):e1381813. doi:10.1080/2162402X.2017.1381813.
   PubMed Web of Science ®Google Scholar
• Spolski R, Li P, Leonard WJ. Biology and Regulation of IL-2: From Molecular Mechanisms to Human Therapy. Nat Rev Immunol. 2018 Oct;18(10):648-659. doi:10.1038/s41577-018-0046-y.
   PubMed Web of Science ®Google Scholar
• Su EW, Moore CJ, Suriano S, Johnson CB, Songalia N, Patterson A, Neitzke DJ, Andrijauskaite K, Garrett-Mayer E, Mehrotra S, et al. IL-2Rα mediates temporal regulation of IL-2 signaling and enhances immunotherapy. Sci Transl Med. 2015;7(311):311ra170–311ra170. doi:10.1126/scitranslmed.aac8155.
   PubMed Web of Science ®Google Scholar
• Rudnicka K, Matusiak A, Chmiela M. CD25 (IL-2R) expression correlates with the target cell induced cytotoxic activity and cytokine secretion in human natural killer cells. Acta Biochim. Pol. 2015;62(4):885–894. doi:10.18388/abp.2015_1152.
   PubMed Web of Science ®Google Scholar
• Bremm M, Pfeffermann L-M, Cappel C, Katzki V, Erben S, Betz S, Quaiser A, Merker M, Bonig H, Schmidt M, et al. Improving clinical manufacturing of IL-15 activated Cytokine-Induced Killer (CIK) cells. Front Immunol. 2019;10:1218. doi:10.3389/fimmu.2019.01218.
   PubMed Web of Science ®Google Scholar
• Linn Y-C, Yong H-X, Niam M, Lim T-J, Chu S, Choong A, Chuah C, Goh Y-T, Hwang W, Loh Y, et al. A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission. Cytotherapy. 2012;14(7):851–859. doi:10.3109/14653249.2012.694419.
   PubMed Web of Science ®Google Scholar
• Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, Dander E, Gaipa G, D’Amico G, Biagi E, et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study1. Haematologica. 2007;92(7):952–959. doi:10.3324/haematol.11132.
   PubMed Web of Science ®Google Scholar
• Linn Y-C, Niam M, Chu S, Choong A, Yong H-X, Heng -K-K, Hwang W, Loh Y, Goh Y-T, Suck G, et al. The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplant. 2012;47(7):957–966. doi:10.1038/bmt.2011.202.
   PubMed Web of Science ®Google Scholar
• Introna M, Gotti E, Bonzi M, Golay J, Algarotti A, Micò C, Grassi A, Boschini C, Ferrari ML, Cavattoni I, et al. A multicenter Phase II study of sequential administration of unmanipulated DLI and donor derived Cytokine Induced Killer (CIK) cells in HSCT patients, relapsed of disease. Blood. 2015;126(23):3160. doi:10.1182/blood.V126.23.3160.3160.
   Web of Science ®Google Scholar
• Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174(1):139–149. doi:10.1084/jem.174.1.139.
   PubMed Web of Science ®Google Scholar
• Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994;153:1687–1696.
   PubMed Web of Science ®Google Scholar
• Nishimura R, Baker J, Beilhack A, Zeiser R, Olson JA, Sega EI, Karimi M, Negrin RS. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood. 2008;112(6):2563–2574. doi:10.1182/blood-2007-06-092817.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J. Immunol. 2014;192(12):5451–5458. doi:10.4049/jimmunol.1490019.
   PubMed Web of Science ®Google Scholar
• Arenas-Ramirez N, Woytschak J, Boyman O. Interleukin-2: biology, design and application. Trends Immunol. 2015 Dec;36(12):763–777. doi:10.1016/j.it.2015.10.003.
   PubMed Web of Science ®Google Scholar